Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.

Cadila Pharmaceuticals Ltd. manufactures and distributes pharmaceutical products. The company is involved in manufacturing pharmaceutical products, new drug discovery, novel drug delivery, analytical research, biosynthesis and genetic engineering. It also manufactures cardiovascular, gastrointestinal, anti inflammatory, antibiotics, vaccines, anti-diabetic and vitamin drugs. The company was founded in 1951 by Indravadan Ambalal Modi and is headquartered in Ahmedabad, India.

Multi Radiance Medical, Inc. manufactures FDA-cleared Super Pulsed Lasers for safe, natural, drug-free and non-invasive pain relief. The firm offers MRE laserstim emitter, MR4 lasershower emitter, MR4 SE25, MR4 ACTI, MR4 ACTIV PRO and MR4 petlaser. The company was founded by Max Kanarsky and is headquartered in Solon, OH.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection.\nThe team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.\nApitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance.\nThe firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds.\nThe company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Kyoto Pharmaceutical Industries Ltd. engages in pharmaceutical products manufacturing. Its products include pharmaceuticals to regulate high-blood pressure, Ischemic heart disease treatment, digitalis formulation, and constipation remedies. The firm also develops and produces laxatives, anti-flatulence and anti-diarrheal medicines, and decongestants and cold medicines. The company was founded on September 5, 1946 and is headquartered in Kyoto, Japan.

Luoyang Suntech Pharmacy Technology Co., Ltd., established on 2016-08-05, Business scope includes medical technology,Biotechnology,Development of new material technology,consult,Serve,transfer;Research and development and sales of plant extracts;Goods and technology import and export business(Except for goods and technologies that the state restricts enterprises to operate or prohibits the import and export of).

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Part of Ligand Pharmaceuticals, Inc., Ligand UK Research Ltd. is a British company located in Berkshire. The firm develops pharmaceutical products.

Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc., initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product.

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

Chengdu Ruimu Biomedical Technology Co., Ltd., established on 2018-04-23, Business scope includes medical technology development,technical consulting,technology transfer,Technical Services(Does not involve human stem cells,Development and application of genetic diagnosis and treatment technology);medicine,plant material,Chemical materials(Free of Hazardous Chemicals),cosmetic,Research and development of health food,Sales,technical consulting,technology transfer;Import and export of goods and technology.(The above business scope does not include items restricted or prohibited by national laws and regulations,Except those involving the implementation of special access management measures stipulated by the state,Business activities involving licenses can only be carried out with relevant licenses).

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergies and other diseases. The company is building a pipeline for allergy and autoimmune diseases based on two technology platforms, PCFiT and Apitope, through internal development and external collaboration with flexible business models. Worg is also developing a platform for molecular allergy diagnosis.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.